Cat. No.: HY-12497

ANA-12

39 Cited Publications

Customer Review

Based on 39 publication(s) in Google Scholar

ANA-12 is a brain-penetrant, selective TrkB antagonist with IC₅₀ values of 45.6 nM and 41.1 μM, and K_d values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory.

For research use only. We do not sell to patients.

Purity: 99.90%
CAS No.: 219766-25-3
Formula: C₂₂H₂₁N₃O₃S
Molecular Weight:407.49

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

ANA-12 Chemical Structure

CAS No.: 219766-25-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (39)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]

TrkB

45.6 nM (IC₅₀)

TrkB

41.1 μM (IC₅₀)

TrkB

10 nM (Kd)

TrkB

12 μM (Kd)

Caspase-1

NLRP3

All Trk Receptor Isoforms :

All NOD-like Receptor (NLR) Isoforms :

All Caspase Isoforms :

In Vitro

ANA-12 (1 μM; 24 h) inhibits the inflammatory response, glial cell activation, and the expression of pro-inflammatory proteins in IL-1β-induced human glioma U251 cells^[1].
ANA-12 exhibits dissociation constants (K_d) of 10 nM and 12 μM for the high- and low-affinity binding sites of TrkB, respectively, in a cell-free system^[4].
ANA-12 (0.1 nM-100 μM; 20 min) inhibits BDNF-induced TrkB receptor autophosphorylation in TetOn-rhTrkB cells expressing human recombinant TrkB (IC₅₀ values: 45.6 nM for the high-affinity site; 87.0 μM for the low-affinity site) and inhibits BDNF-induced TrkB receptor activation in primary mouse cortical neurons (IC₅₀ values: 45.6 nM for the high-affinity site; 41.1 μM for the low-affinity site)^[4].
ANA-12 (0.01 μM-100 μM; 3 days) dose-dependently blocks BDNF (1 nM) (HY-P7116)-induced neurite outgrowth in nnr5 PC12-TrkB cells stably transfected with TrkB, but does not exert this inhibitory effect in cells expressing TrkA or TrkC^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:

U251 cells
Concentration:

1 μM
Incubation Time:

24 h
Result:

Decreased the signal intensities of BDNF, NLRP3, IL-1β, and GFAP.

Western Blot Analysis^[1]

Cell Line:

U251 cells
Concentration:

1 μM
Incubation Time:

24 h
Result:

Decreased the protein levels of GFAP, Iba-1, BDNF, pTrkB, pMAPK, NLRP3, caspase-1, NLRC4, and AIM2.

ELISA Assay^[4]

Cell Line:

TetOn-rhTrkB cells, Cortical neurons
Concentration:

0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
Incubation Time:

20 min
Result:

Completely blocked the TrkB autophosphorylation induced by BDNF.
Significantly reduced BDNF-induced TrkB receptor activity through a noncompetitive mechanism and exhibited high and low-affinity binding modes.

In Vivo

ANA-12 (0.5 mg/kg; i.p.; once daily for 7 consecutive days (days 15–21); tested 4 hours after administration) exhibits significant analgesic activity and improves motor coordination in a type II collagen (HY-NP003)-induced arthritis (CIA) mouse model; it also significantly inhibits central glial cell activation and reduces neuroinflammation^[1]. ANA-12 (0.25 μg; intra-NAc shell microinjection; administered 30 minutes prior to stress on days 1, 4, 7, and 10) enhances social interaction, improves conditioned place preference, and facilitates passive avoidance memory in adult male Wistar rats subjected to 10 days of chronic unpredictable stress^[2].
ANA-12 (0.5-1.0 mg/kg; i.p.; single dose; administered immediately or 6 hours after the memory reactivation phase) impairs memory reconsolidation in the novel object recognition (NOR) test using ICR mice^[3].
ANA-12 (0.5 mg/kg; i.p.; single dose; tested 4 hours post-administration) exhibits significant anxiolytic and antidepressant effects in normal mice^[4].
ANA-12 (0.5-2.0 mg/kg; i.p.; once daily for 7 days) demonstrates a favorable in vivo safety profile in normal mice^[4].
ANA-12 (0.5 mg/kg; i.p.; single dose; administered 2 days after the final stress session) exhibits rapid antidepressant activity in a social defeat stress model using male C57BL/6 mice^[5].
ANA-12 (0.5 mg/kg; i.p.; single dose; administered on day 8 post-injury) did not ameliorate the anhedonia-like phenotype induced by neuropathic pain in a spared nerve injury (SNI) rat model, but it significantly attenuated the SNI-induced abnormal elevation of BDNF-TrkB signaling in the nucleus accumbens (NAc)^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CIA mouse model was established by intradermal and subcutaneous injections of bovine type II collagen (CII) and CFA emulsion^[1]
Dosage:

0.5 mg/kg
Administration:

i.p.; once daily; for 7 days
Result:

Decreased the number of spontaneous flinches, and increased the mechanical and thermal paw withdrawal thresholds.
Reduced the fluorescence signals of activated astrocytes and microglia in the locus coeruleus (LC).
Decreased the fluorescence intensities of BDNF, pTrkB, pMAPK, and inflammasome-related proteins in the LC.

Animal Model:

10-day heterotypic stress paradigm (alternating restraint and forced swim stress) in Wistar rats^[2]
Dosage:

0.25 μg
Administration:

Intra-NAc shell infusion (0.5 μL); administered on days 1, 4, 7, and 10; 10 days.
Result:

Increased the sociability ratio in stressed rats during the social interaction test.
Increased the time spent in the food-paired arm during the conditioned place preference test.
Prolonged the latency to re-enter the aversive arm in the Y-maze passive avoidance task.

Animal Model:

Normal ICR mice underwent the novel object recognition (NOR) test without specific surgical/stress modeling^[3]
Dosage:

0.5 or 1.0 mg/kg
Administration:

i.p.; single dose; injected immediately or 6 h after the reactivation phase
Result:

Significantly decreased the discrimination index and impaired memory reconsolidation when injected at 1.0 mg/kg immediately after reactivation.
Showed no effect on memory performance when injected 6 h post-reactivation or without a reactivation phase.

Animal Model:

Naive adult C57BL6/129SveV hybrid mice without special stress/surgical modeling^[4]
Dosage:

0.5 mg/kg
Administration:

i.p.; single dose; 4 h
Result:

Increased the number of entries and time spent in the open arms of the elevated plus maze.
Shortened the latency to feed in the novelty-suppressed feeding test.
Significantly decreased immobility time in the forced swimming and tail suspension tests.

Animal Model:

Naive adult C57BL6/129SveV hybrid mice without special stress/surgical modeling^[4]
Dosage:

0.5, 1.0, 2.0 mg/kg
Administration:

i.p.; once daily; for 7 days
Result:

Did not induce neuronal apoptosis in the brain after 7 days of consecutive injections at low/mid doses.

Animal Model:

Social defeat stress depression model established by 10-day exposure to CD1 aggressor mice^[5]
Dosage:

0.5 mg/kg
Administration:

i.p.; single dose; treated/tested on day 12
Result:

Significantly reduced immobility time in the tail suspension and forced swimming tests in depressed mice.
Improved sucrose preference 1 and 3 days post-dose, but the effect disappeared by day 7.
Did not reverse the stress-induced reduction of BDNF and PSD-95 protein.

Animal Model:

Spared nerve injury (SNI) rat model established by ligating and cutting the common peroneal and tibial nerves while sparing the sural nerve^[7]
Dosage:

0.5 mg/kg
Administration:

i.p.; single dose; treated on day 8 after nerve injury
Result:

Failed to restore the decreased mechanical withdrawal threshold (MWT) and sucrose preference in anhedonia-susceptible SNI rats.
Failed to improve the reduced BDNF and p-TrkB levels in the mPFC.
Significantly attenuated the SNI-induced abnormal elevation of BDNF and p-TrkB levels in the nucleus accumbens (NAc).

Chemical Information

CAS No. 219766-25-3
Appearance Solid
Molecular Weight 407.49
Formula C₂₂H₂₁N₃O₃S
Color White to off-white
SMILES

O=C(C1=CC2=CC=CC=C2S1)NC3=CC=CC=C3C(NC4C(NCCCC4)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (39)

All WBIF

Sort by:

Journal Impact Factor

Cell Metab

Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies. [Abstract]

2022 Dec 6;34(12):1999-2017.e10. PMID: 36395769
Nat Commun

Mesenchymal stromal cells alleviate depressive and anxiety-like behaviors via a lung vagal-to-brain axis in male mice. [Abstract]

2023 Nov 16;14(1):7406. PMID: 37973914
Adv Sci (Weinh)

Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4-Mediated Acute Hepatitis. [Abstract]

2026 Mar 25:e21164. PMID: 41881032
J Neuroinflammation

Inhibition of P2X4R attenuates white matter injury in mice after intracerebral hemorrhage by regulating microglial phenotypes. [Abstract]

2021 Aug 23;18(1):184. PMID: 34425835

ANA-12 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2021 Aug 23;18(1):184. [Abstract]

ANA-12 (0.5 mg/kg/day, i.p., daily for 7 days, from 1 day before ICH) reversed the treatment effect of inhibition P2X4R on white matter injury after ICH.

ANA-12 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2021 Aug 23;18(1):184. [Abstract]

ANA-12 (0.5 mg/kg/day, i.p., daily for 7 days, from 1 day before ICH) reversed the treatment effect of inhibition P2X4R on white matter injury after ICH.
J Neuroinflammation

BDNF promotes activation of astrocytes and microglia contributing to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis. [Abstract]

2020 Jan 13;17(1):19. PMID: 31931832

ANA-12 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2020 Jan 13;17(1):19. [Abstract]

ANA-12 (0.5 mg/kg, i.p., every other day after CYP injection, from day 3 to day 9) restrained activation of astrocytes and microglia induced by CYP.
Phytomedicine

Xiaochaihutang ameliorates depression-like behaviors induced via chronic social defeat stress by regulating exon-specific Bdnf transcription through H3K18 acetylation in the hippocampus of mice. [Abstract]

2025 May:140:156567. PMID: 40068295
Phytomedicine

Astragaloside IV mediates radiation-induced neuronal damage through activation of BDNF-TrkB signaling. [Abstract]

2024 Sep:132:155803. PMID: 38876008
J Transl Med

Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models. [Abstract]

2025 Aug 14;23(1):915. PMID: 40813987
Neural Regen Res

Electroacupuncture treatment improves motor function and neurological outcomes after cerebral ischemia/reperfusion injury. [Abstract]

2022 Jul;17(7):1545-1555. PMID: 34916440
Phytother Res

Salidroside directly activates HSC70, revealing a new role for HSC70 in BDNF signalling and neurogenesis after cerebral ischemia. [Abstract]

2024 Jun;38(6):2619-2640. PMID: 38488455
Cell Prolif

Flavonoid chrysin activates both TrkB and FGFR1 receptors while upregulates their endogenous ligands such as brain derived neurotrophic factor to promote human neurogenesis. [Abstract]

2025 Jan;58(1):e13732. PMID: 39331585
Transl Psychiatry

The causal involvement of the BDNF-TrkB pathway in dentate gyrus in early-life stress-induced cognitive deficits in male mice. [Abstract]

2023 May 24;13(1):173. PMID: 37225683
Chin Med

Electroacupuncture promotes BDNF-dependent neurogenesis via microglial reprogramming in a chronic stress model. [Abstract]

2026 Feb 3;21(1):62. PMID: 41634791
PLoS Biol

Mdga2 deficiency leads to an aberrant activation of BDNF/TrkB signaling that underlies autism-relevant synaptic and behavioral changes in mice. [Abstract]

2025 Apr 1;23(4):e3003047. PMID: 40168357
Neurosci Bull

Peripheral BDNF Regulates Somatosensory-Sympathetic Coupling in Brachial Plexus Avulsion-Induced Neuropathic Pain. [Abstract]

2023 Dec;39(12):1789-1806. PMID: 37335428
Ecotoxicol Environ Saf

Amelioration of cholesterol sulfate for lead-induced CTX cell apoptosis based on BDNF signaling pathway mediated cholesterol metabolism. [Abstract]

2022 Dec 15:248:114307. PMID: 36423370
Drug Des Devel Ther

Edaravone Alleviated Propofol-Induced Neurotoxicity in Developing Hippocampus by mBDNF/TrkB/PI3K Pathway. [Abstract]

2021 Mar 30:15:1409-1422. PMID: 33833500
J Ovarian Res

BDNF promotes mouse follicular development and reverses ovarian aging by promoting cell proliferation. [Abstract]

2023 Apr 27;16(1):83. PMID: 37106468
Mol Med Rep

Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis. [Abstract]

2018 May;17(5):6211-6226. PMID: 29512753
J Cell Mol Med

Engeletin alleviates depression-like phenotype by increasing synaptic plasticity via the BDNF-TrkB-mTORC1 signalling pathway. [Abstract]

2023 Dec;27(23):3928-3938. PMID: 37799103
J Neurosci

A Time-Sensitive Plasticity Distinguishes the Rapid and Sustained Synaptic Actions of Ketamine from Its (2 R,6 R)-Hydroxynorketamine Metabolite. [Abstract]

2026 Feb 3:e0958252026. PMID: 41633835
Front Neurosci

Tetramethylpyrazine Alleviates Behavioral and Psychological Symptoms of Dementia Through Facilitating Hippocampal Synaptic Plasticity in Rats With Chronic Cerebral Hypoperfusion. [Abstract]

2021 May 6:15:646537. PMID: 34025340
ACS Pharmacol Transl Sci

Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth. [Abstract]

2020 Sep 11;4(2):452-460. PMID: 33860174
Eur Arch Psychiatry Clin Neurosci

Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury. [Abstract]

2020 Mar;270(2):195-205. PMID: 29882089
Brain Sci

The α-7 Nicotinic Receptor Positive Allosteric Modulator Alleviates Lipopolysaccharide Induced Depressive-like Behavior by Regulating Microglial Function, Trophic Factor, and Chloride Transporters in Mice. [Abstract]

2024 Mar 19;14(3):290. PMID: 38539677
Neuroscience

Brain-derived neurotrophic factor in the ventrolateral orbital cortex regulates spared nerve injury-induced neuropathic pain and related emotional disorders in mice. [Abstract]

2025 Aug 20:584:250-263. PMID: 40846211
Neuroscience

Sulforaphane Alleviates Lipopolysaccharide-induced Spatial Learning and Memory Dysfunction in Mice: The Role of BDNF-mTOR Signaling Pathway. [Abstract]

2018 Sep 15:388:357-366. PMID: 30086367

ANA-12 purchased from MedChemExpress. Usage Cited in: Neuroscience. 2018 Sep 15:388:357-366. [Abstract]

Effects of ANA-12 on inflammatory cytokines, synaptic proteins, BDNF-TrkB signaling pathways in mice treated with Sulforaphane (SFN) plus Lipopolysaccharide (LPS).
Exp Eye Res

Neurotrophin-4 as a promising therapy for corneal injuries: Enhancing epithelial repair and nerve regeneration in abrasion and alkali burn models. [Abstract]

2026 May:266:110917. PMID: 41679583
Tissue Cell

BDNF alleviates senescence and enhances osteogenic differentiation in bone marrow mesenchymal stem cells via the TrkB/PI3K/AKT pathway. [Abstract]

2025 Oct:96:102972. PMID: 40367890
Exp Eye Res

Neuroprotective effects of methyl 3,4 dihydroxybenzoate in a mouse model of retinitis pigmentosa. [Abstract]

2017 Sep:162:86-96. PMID: 28709891

ANA-12 purchased from MedChemExpress. Usage Cited in: Exp Eye Res. 2017 Sep:162:86-96. [Abstract]

Blocking the BDNF pathway with ANA-12 prevents the protective effect of MDHB.
Behav Brain Res

Sigma-1 receptor agonist PRE-084 increases BDNF by activating the ERK/CREB pathway to rescue learning and memory impairment caused by type II diabetes. [Abstract]

2025 Apr 27:484:115493. PMID: 39986614
Biochem Biophys Res Commun

Cordycepin buffers anisomycin-induced fear memory deficit by restoring hippocampal BDNF. [Abstract]

2023 Jul 12:665:118-123. PMID: 37156049
Sleep Breath

7,8-Dihydroxyflavone protects retinal ganglion cells against chronic intermittent hypoxia-induced oxidative stress damage via activation of the BDNF/TrkB signaling pathway. [Abstract]

2022 Mar;26(1):287-295. PMID: 33993395
J Neurophysiol

cAMP-dependent protein kinase signaling is required for ( 2R,6R)-hydroxynorketamine to potentiate hippocampal glutamatergic transmission. [Abstract]

2024 Jan 1;131(1):64-74. PMID: 38050689
Neurosci Lett

P2X4 receptor in the dorsal horn contributes to BDNF/TrkB and AMPA receptor activation in the pathogenesis of remifentanil-induced postoperative hyperalgesia in rats. [Abstract]

2021 Apr 17:750:135773. PMID: 33639220
Exp Ther Med

The activation of BDNF reduced inflammation in a spinal cord injury model by TrkB/p38 MAPK signaling. [Abstract]

2019 Mar;17(3):1688-1696. PMID: 30783437
Biomed Pharmacother

Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside against cadmium toxicity involve BDNF/TrkB and PI3K/Akt signaling pathways. [Abstract]

2025 Nov:192:118602. PMID: 41135432
Research Square Print

November 21st, 2022.
Patent

US20200030309A1

Solvent & Solubility

In Vitro:

DMSO : 7.69 mg/mL (18.87 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4540 mL

12.2702 mL

24.5405 mL

5 mM

0.4908 mL

2.4540 mL

4.9081 mL

10 mM

0.2454 mL

1.2270 mL

2.4540 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 1.43 mg/mL (3.51 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.43 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.43 mg/mL (3.51 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: 1 mg/mL (2.45 mM); Suspended solution; Need ultrasonic

Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.45 mg/mL (1.10 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% Corn Oil

Solubility: ≥ 0.45 mg/mL (1.10 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2 mg/mL (4.91 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (297 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yuan M, et al. ANA-12 Targets and Inhibits BDNF/TrkB Signaling to Alleviate Pain Behaviors in Rheumatoid Arthritis Mice. Neurochem Res. 2025 Jul 17;50(4):234. [Content Brief]

[2]. Azogu I, et al. Inhibition of TrkB at the nucleus accumbens, using ANA-12, regulates basal and stress-induced orexin A expression within the mesolimbic system and affects anxiety, sociability and motivation. Neuropharmacology. 2017 Oct;125:129-145. [Content Brief]

[3]. Tan P, et al. TrkB receptor antagonist ANA-12 impairs memory reconsolidation in novel object recognition task via regulation of hippocampal transcriptome. Neurobiol Learn Mem. 2026 Mar;224:108141. [Content Brief]

[4]. Cazorla M, et al. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest. 2011 May;121(5):1846-57. [Content Brief]

[5]. Zhang JC, et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 2015 Dec;232(23):4325-35. [Content Brief]

[6]. Vassoler FM, et al. Epigenetic inheritance of a cocaine-resistance phenotype. Nat Neurosci. 2013 Jan;16(1):42-7. [Content Brief]

[7]. Fang X, et al. Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury. Eur Arch Psychiatry Clin Neurosci. 2020 Mar;270(2):195-205. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4540 mL	12.2702 mL	24.5405 mL	61.3512 mL
	5 mM	0.4908 mL	2.4540 mL	4.9081 mL	12.2702 mL
	10 mM	0.2454 mL	1.2270 mL	2.4540 mL	6.1351 mL
	15 mM	0.1636 mL	0.8180 mL	1.6360 mL	4.0901 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

ANA-12

Bioactive Compound Library Max

Bioactive Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Kinase Inhibitor Library Mini

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) ANA-12

All Trk Receptor Isoforms

All NOD-like Receptor (NLR) Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Publications (39)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

ANA-12

Bioactive Compound Library Max

Bioactive Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Kinase Inhibitor Library Mini

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) ANA-12

All Trk Receptor Isoforms

All NOD-like Receptor (NLR) Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Publications (39)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

ANA-12 Related Classifications

HY-12497 Related Classifications